Table 3 Risk Factors for clinical and microbiological outcomes in pediatric MRSA bacteremia
30-day all-cause mortality (n = 8) | Persistent bacteremia at day 7 (n = 9) | |||||
|---|---|---|---|---|---|---|
n (%) | OR (95% CI) | aOR (95% CI) | n (%) | OR (95% CI) | aOR (95% CI) | |
Age (years) | - | 0.96 (0.82–1.13) | NA | - | 1.067 (0.95–1.2) | NA |
Hospital onset | 7 (87.5) | 3.06 (0.35–26.48) | NA | 8 (88.9) | 3.73 (0.44–31.8) | NA |
Primary source of infection | ||||||
None | 3 (37.5) | 2.85 (0.60–13.57) | 4.51 (0.71–28.73) | 0 (0.0) | NA | NA |
CVC infection | 3 (37.5) | 0.55 (0.12–2.48) | NA | 5 (55.6) | 1.18 (0.29–4.77) | NA |
Pneumonia | 1 (12.5) | 1.83 (0.19–17.96) | NA | 3 (33.3) | 10.5 (1.73–63.91) | 8.63 (1.25–56.62) |
BJI & SSTI | 0 (0.0) | NA | NA | 0 (0.0) | NA | NA |
SSI | 1 (12.5) | 3.14 (0.29–34.42) | NA | 1 (11.1) | 2.63 (0.24–28.36) | NA |
IE | 0 (0.0) | NA | NA | 0 (0.0) | NA | NA |
Severe presentation | 1 (12.5) | 0.68 (0.08–6.04) | NA | 2 (22.2) | 1.429(0.26–7.82) | NA |
Vancomycin MIC = 2 (µg/mL) | 1 (12.5) | 1.83 (0.19–17.96) | NA | 1 (11.1) | 1.525(0.16–14.76) | NA |
ST groups | ||||||
ST1 group a | 3 (37.5) | 39.0 (3.40–444.06) | 44.12 (3.46–562.19) | 2 (22.2) | 17.71 (1.42–221.15) | 14.37 (0.96–216.06) |
ST5 group b | 0 (0.0) | NA | NA | 1 (11.1) | 0.48 (0.06–4.20) | NA |
ST72 group c | 5 (62.5) | 0.78 (0.17–3.56) | NA | 5 (55.6) | 0.54 (0.13–2.23) | NA |